Part of Yale Cardiovascular Research Group and directed by Lissa Sugeng, YECL provides echocardiographic core lab services for clinical trials involving drug or device therapies. Currently, there are several clinical trials overseen by YECL:
Harlan Krumholz and Robert McNamara investigate quality and outcomes on a national scale. Locally, Robert McNamara and Rachel Lampert, from the Electrophysiology group, are conducting a study identifying potential candidates for intracardiac cardioverter defibrillators (ICD’s) with a notation on the echo report of patients with left ventricular ejection fraction less than or equal to 35%.
Raymond Russell from the Nuclear Cardiology Group, directs the Cardio-Oncology collaboration with members from the Oncology section. His expertise in cellular signaling and cellular metabolism facilitate translational research to improve investigation into the effects of various chemotherapeutic agents.
A pioneer in using and assessing 3D technology, Lissa Sugeng has brought valuable expertise to ongoing institutional efforts in assessment of myocardial function using of 3D strain as well as novel approaches to the assessment and treatment of valvular heart disease.
The Echo Lab provides support for other research efforts within the institution. Programs include those investigating hereditary hemorrhagic telangectasia (Osler-Weber-Rendu), Gauchers Disease, and first-pass radionucleotide validation. The Echo Lab also supports multiple efforts in therapeutic trials for eligibility and outcomes.